Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SGTX

Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

Sigilon Therapeutics logo

About Sigilon Therapeutics Stock (NASDAQ:SGTX)

Key Stats

Today's Range
$22.09
$23.10
50-Day Range
$20.92
$23.06
52-Week Range
$3.77
$28.00
Volume
83,600 shs
Average Volume
62,902 shs
Market Capitalization
$56.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive SGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SGTX Stock News Headlines

Lilly & Co Eli's Net Worth
MCRB Seres Therapeutics, Inc.
I've got news for you…
Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week
Beam Therapeutics Inc.
Eli Lilly Concludes Acquisition Of Sigilon Therapeutics
Lilly Completes Acquisition of Sigilon Therapeutics
SGTX - Sigilon Therapeutics, Inc.
See More Headlines

SGTX Stock Analysis - Frequently Asked Questions

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($8.19) EPS for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The company had revenue of $1.95 million for the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative net margin of 171.29% and a negative trailing twelve-month return on equity of 83.07%.

Sigilon Therapeutics shares reverse split on the morning of Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Sigilon Therapeutics (SGTX) raised $101 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 5,600,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sigilon Therapeutics investors own include Tesla (TSLA), NIO (NIO), Athenex (ATNX), Palantir Technologies (PLTR), Plug Power (PLUG), CrowdStrike (CRWD) and Li Auto (LI).

Company Calendar

Last Earnings
11/10/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SGTX
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Net Income
$-43,560,000.00
Net Margins
-171.29%
Pretax Margin
-171.29%

Debt

Sales & Book Value

Annual Sales
$12.94 million
Book Value
$15.68 per share

Miscellaneous

Free Float
2,351,000
Market Cap
$56.40 million
Optionable
Not Optionable
Beta
4.12
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:SGTX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners